Subscribe To
BTAI / Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week
BTAI News
By PennyStocks
October 30, 2023
4 Penny Stocks To Watch Today With Big News, Time To Buy?
Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or more_horizontal
By PennyStocks
October 26, 2023
3 Penny Stocks To Buy For Under $5, Are They Worth It?
Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroo more_horizontal
By InvestorPlace
October 25, 2023
Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?
BioXcel Therapeutics (NASDAQ: BTAI ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its more_horizontal
By Market Watch
October 25, 2023
BioXcel Therapeutics shares pop after audit of Alzheimer's trial data
Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of Alzheimer' more_horizontal
By The Motley Fool
September 28, 2023
Why Shares of BioXcel Therapeutics Fell This Week
The company has one marketed treatment -- Igalmi, which reduces agitation in patients with bipolar disorder or schizophrenia. The most advanced candid more_horizontal
By The Motley Fool
August 15, 2023
Why BioXcel Therapeutics Stock Flopped Again Today
The biotech takes another hit following its earnings release on Monday. Several analysts became notably more bullish on its prospects. more_horizontal
By InvestorPlace
August 14, 2023
3 Biotech Stocks to Sell in August Before They Crash and Burn
Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher tha more_horizontal
By The Motley Fool
August 14, 2023
Why BioXcel Therapeutics Stock Is Getting Crushed Today
BioXcel announced Q2 results and a major strategic shift this morning. The biotech specialist has halted plans for Phase 2 clinical trials that were i more_horizontal